AllergoOncology – the impact of allergy in oncology: EAACI position paper

E. Jensen-Jarolim, H. J. Bax, R. Bianchini, M. Capron, C. Corrigan, M. Castells, David Dombrowicz, T. R. Daniels-Wells, J. Fazekas, E. Fiebiger, S. Gatault, H. J. Gould, J. Janda, D. H. Josephs, P. Karagiannis, F. Levi-Schaffer, A. Meshcheryakova, D. Mechtcheriakova, Y. Mekori, F. MungenastElisa A. Nigro, M. L. Penichet, F. Redegeld, L. Saul, J. Singer, J. F. Spicer, Antonio G. Siccardi, E. Spillner, M. C. Turner, E. Untersmayr, L. Vangelista, S. N. Karagiannis

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.

Original languageEnglish
Pages (from-to)866-887
Number of pages22
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume72
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Hypersensitivity
Immunoglobulin E
Neoplasms
Antibodies
Cross-Priming
Synthetic Vaccines
Medical Oncology
Immunomodulation
Antigen Presentation
Neoplasm Antigens
Advisory Committees
Allergy and Immunology
Focus Groups
Immunotherapy
Allergens
Dendritic Cells
Immunity
Parasites
Therapeutics

Keywords

  • AllergoOncology
  • allergy
  • atopy
  • biologics, desensitization
  • cancer
  • chemotherapeutic
  • clinical oncology
  • IgE
  • IgG4
  • inflammation
  • tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Jensen-Jarolim, E., Bax, H. J., Bianchini, R., Capron, M., Corrigan, C., Castells, M., ... Karagiannis, S. N. (2017). AllergoOncology – the impact of allergy in oncology: EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 72(6), 866-887. https://doi.org/10.1111/all.13119

AllergoOncology – the impact of allergy in oncology : EAACI position paper. / Jensen-Jarolim, E.; Bax, H. J.; Bianchini, R.; Capron, M.; Corrigan, C.; Castells, M.; Dombrowicz, David; Daniels-Wells, T. R.; Fazekas, J.; Fiebiger, E.; Gatault, S.; Gould, H. J.; Janda, J.; Josephs, D. H.; Karagiannis, P.; Levi-Schaffer, F.; Meshcheryakova, A.; Mechtcheriakova, D.; Mekori, Y.; Mungenast, F.; Nigro, Elisa A.; Penichet, M. L.; Redegeld, F.; Saul, L.; Singer, J.; Spicer, J. F.; Siccardi, Antonio G.; Spillner, E.; Turner, M. C.; Untersmayr, E.; Vangelista, L.; Karagiannis, S. N.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, No. 6, 01.06.2017, p. 866-887.

Research output: Contribution to journalArticle

Jensen-Jarolim, E, Bax, HJ, Bianchini, R, Capron, M, Corrigan, C, Castells, M, Dombrowicz, D, Daniels-Wells, TR, Fazekas, J, Fiebiger, E, Gatault, S, Gould, HJ, Janda, J, Josephs, DH, Karagiannis, P, Levi-Schaffer, F, Meshcheryakova, A, Mechtcheriakova, D, Mekori, Y, Mungenast, F, Nigro, EA, Penichet, ML, Redegeld, F, Saul, L, Singer, J, Spicer, JF, Siccardi, AG, Spillner, E, Turner, MC, Untersmayr, E, Vangelista, L & Karagiannis, SN 2017, 'AllergoOncology – the impact of allergy in oncology: EAACI position paper', Allergy: European Journal of Allergy and Clinical Immunology, vol. 72, no. 6, pp. 866-887. https://doi.org/10.1111/all.13119
Jensen-Jarolim, E. ; Bax, H. J. ; Bianchini, R. ; Capron, M. ; Corrigan, C. ; Castells, M. ; Dombrowicz, David ; Daniels-Wells, T. R. ; Fazekas, J. ; Fiebiger, E. ; Gatault, S. ; Gould, H. J. ; Janda, J. ; Josephs, D. H. ; Karagiannis, P. ; Levi-Schaffer, F. ; Meshcheryakova, A. ; Mechtcheriakova, D. ; Mekori, Y. ; Mungenast, F. ; Nigro, Elisa A. ; Penichet, M. L. ; Redegeld, F. ; Saul, L. ; Singer, J. ; Spicer, J. F. ; Siccardi, Antonio G. ; Spillner, E. ; Turner, M. C. ; Untersmayr, E. ; Vangelista, L. ; Karagiannis, S. N. / AllergoOncology – the impact of allergy in oncology : EAACI position paper. In: Allergy: European Journal of Allergy and Clinical Immunology. 2017 ; Vol. 72, No. 6. pp. 866-887.
@article{1f19ffd1ead1410c9d37da9f0c4c1547,
title = "AllergoOncology – the impact of allergy in oncology: EAACI position paper",
abstract = "Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.",
keywords = "AllergoOncology, allergy, atopy, biologics, desensitization, cancer, chemotherapeutic, clinical oncology, IgE, IgG4, inflammation, tumor",
author = "E. Jensen-Jarolim and Bax, {H. J.} and R. Bianchini and M. Capron and C. Corrigan and M. Castells and David Dombrowicz and Daniels-Wells, {T. R.} and J. Fazekas and E. Fiebiger and S. Gatault and Gould, {H. J.} and J. Janda and Josephs, {D. H.} and P. Karagiannis and F. Levi-Schaffer and A. Meshcheryakova and D. Mechtcheriakova and Y. Mekori and F. Mungenast and Nigro, {Elisa A.} and Penichet, {M. L.} and F. Redegeld and L. Saul and J. Singer and Spicer, {J. F.} and Siccardi, {Antonio G.} and E. Spillner and Turner, {M. C.} and E. Untersmayr and L. Vangelista and Karagiannis, {S. N.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/all.13119",
language = "English",
volume = "72",
pages = "866--887",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley Blackwell",
number = "6",

}

TY - JOUR

T1 - AllergoOncology – the impact of allergy in oncology

T2 - EAACI position paper

AU - Jensen-Jarolim, E.

AU - Bax, H. J.

AU - Bianchini, R.

AU - Capron, M.

AU - Corrigan, C.

AU - Castells, M.

AU - Dombrowicz, David

AU - Daniels-Wells, T. R.

AU - Fazekas, J.

AU - Fiebiger, E.

AU - Gatault, S.

AU - Gould, H. J.

AU - Janda, J.

AU - Josephs, D. H.

AU - Karagiannis, P.

AU - Levi-Schaffer, F.

AU - Meshcheryakova, A.

AU - Mechtcheriakova, D.

AU - Mekori, Y.

AU - Mungenast, F.

AU - Nigro, Elisa A.

AU - Penichet, M. L.

AU - Redegeld, F.

AU - Saul, L.

AU - Singer, J.

AU - Spicer, J. F.

AU - Siccardi, Antonio G.

AU - Spillner, E.

AU - Turner, M. C.

AU - Untersmayr, E.

AU - Vangelista, L.

AU - Karagiannis, S. N.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.

AB - Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.

KW - AllergoOncology

KW - allergy

KW - atopy

KW - biologics, desensitization

KW - cancer

KW - chemotherapeutic

KW - clinical oncology

KW - IgE

KW - IgG4

KW - inflammation

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=85010387157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010387157&partnerID=8YFLogxK

U2 - 10.1111/all.13119

DO - 10.1111/all.13119

M3 - Article

AN - SCOPUS:85010387157

VL - 72

SP - 866

EP - 887

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 6

ER -